Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type- V; G/ s9 K4 t' `4 x; |9 X# m& `/ T; m
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * Y* j! l3 _: `& E( i" i
+ Author Affiliations J8 s4 U/ f" B3 R9 _* @
" G" k# U; Q0 O1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
: o8 y! d& e$ a7 }2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
8 P# S2 Y: a- @: e; U; ?3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) ]- r4 T% h: o
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan . o* H- F U, Q- @" n" B$ E
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, ] c( E. j; Z( S6 k! ^9 A: {1 P6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : E5 _1 i: k4 S9 }& r. t6 k
7Kinki University School of Medicine, Osaka 589-8511, Japan $ w% b% e. A$ e) b* ?
8Izumi Municipal Hospital, Osaka 594-0071, Japan * ]; u% X; Z% j; @* R
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
1 x; \0 o& `( J6 Q8 {Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 1 W& _% a2 o. r% y5 i
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
o. {3 v1 z: W: O$ \% \! U
. i' C ?/ }$ P% P c. \- E |